NASDAQ
No price data available for this timeframe.
Cytokinetics, Incorporated (CYTK) has a price/fcf ratio of -14.26x as of Monday, May 25, 2026. This represents a 11.03% increase compared to its 12-month average of -16.03x. The price-to-free-cash-flow ratio measures a stock's price relative to its free cash flow per share, reflecting how efficiently a company generates cash.